A Phase 2/3 interventional study of AD17002 + Formulation buffer and Placebo in COVID-19, sponsored by Advagene Biopharma Co. Ltd.. Terminated at 3 sites in Indonesia. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-09-10.
Sponsored by Advagene Biopharma Co. Ltd. · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 90 studies in COVID-19 with a site in Indonesia — 7 open to participants now, 9 under way, 3 of them phase 3. COVID-19 · Indonesia.
Among the 90 studies in COVID-19 with a site in Indonesia, this one is the 29th largest by enrollment of the 71 interventional ones that give a count, is one of 19 that started in 2022, is one of 9 in phase 2/3, and was the 63rd registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →7 of the 90 studies in COVID-19 with a site in Indonesia are open now. Recruiting first, the newest first:
Dr. Soetomo General Hospital · Sites in Indonesia
Ages 18+ · Healthy volunteers
Indonesia University · Sites in Indonesia
Ages 21–80 · Healthy volunteers
Dr. Soetomo General Hospital · Sites in Indonesia
Ages 12–17 · Women only · Healthy volunteers
Universitas Indonesia · Sites in Indonesia
Ages 12–17 · Healthy volunteers
Indonesia University · Sites in Indonesia
Ages 18+
A study can be open while its sites in Indonesia have not opened yet or have stopped. Only those recruiting at a site in Indonesia →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
90 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 26 · Phase 3 25
First in 2020; this study’s year is marked. 19 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 180 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 120 across the 71 interventional studies, 260 across the 19 observational. Of the 53 that completed or were terminated, 1 (2%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 90 have an industry lead sponsor. The 10 most frequent:
Advagene Biopharma Co. Ltd. is the lead sponsor of 7 studies on the registry; 1 is open to participants now.
Advagene Biopharma Co. Ltd. has 2 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 90 studies in COVID-19 with a site in Indonesia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
AD17002 enhances nasal mucosal innate immunity and has met safety and efficacy endpoints in studies of nasal adjuvants or intranasal immunomodulators. This study aims to evaluate the safety and effectiveness of AD17002 in treating patients with mild to moderate COVID-19.
All participants will be randomly divided into 1:1:1 groups and will receive standard treatment. Additionally, participants will be given either a placebo, 20, or 40 μg of AD17002 via intranasal delivery, and clinical progress will be compared.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have a mild or moderate form of COVID-19 defined as:
respiratory rate ≤30 breaths per minute, heart rate ≤125 beats per minute; with saturation of oxygen (SpO2) ≥93% on room air at sea level No clinical signs listed in Inclusion Criteria #3 indicative of Severe Severity
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive placebo (formulation buffer) on treatment days 1, 3 and 5.
Biological: Placebo
Participants will receive 20 μg of AD17002 in formulation buffer on treatment days 1, 3 and 5.
Biological: AD17002 + Formulation buffer
Participants will receive 40 μg of AD17002 in formulation buffer on treatment days 1, 3 and 5.
Biological: AD17002 + Formulation buffer
Intranasal innate immune modulator
Also known as: LTh(αK)
Formulation buffer
Also known as: Formulation buffer control
Time to disease improvement
Defined as time to achieving ≥1 decrease on WHO 11-point Clinical Progression Scale
Time frame: [Day 1 to Day 29]
Time to achieving the Patient Acceptable Symptom State (PASS)
Defined as the value of symptoms the patient considered to be well-being thresholds of the symptoms and function. The study incorporates the most widely used anchoring question to identify PASS cut-off points, which is: "Taking into account all your daily activities, do you consider your current state satisfactory in relation to pain level and functional impairment?" The response options were "Yes" or "No.
Time frame: [Day 1 to Day 29]
Vital signs evaluation
Measuring the changes to cardiac functions
Time frame: [Day 1 to Day 29]
Physical examination
Measuring changes to physical appearances.
Time frame: [Day 1 to Day 29]
Clinical laboratory assessment
Assessing the changes to hematological parameters
Time frame: [Day 1 to Day 29]
Adverse events assessment
Adverse events graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 Grade 1 (Mild) : asymptomatic or mild symptoms Grade 2 (Moderate): Local, Minimal, Moderate or noninvasive Grade 3 (Severe): Severe or medically significant but not immediately life-threatening Grade 4 (Life-threatening): Life-threatening consequences; urgent intervention indicated Grade 5 (Fatal): Death related to AE
Time frame: [Day 1 to Day 29]
Treatment-emergent adverse events assessment (TEAE)
Measuring the proportion of participants with TEAE leading to investigational medicinal products (IMPs) discontinuation. AE will be presented by the following categories: Any TEAE Treatment-related TEAE Grade 3-4, drug-related TEAE Drug-related TEAE leading to death
Time frame: [Day 1 to Day 29]
Nasal tolerability examination
Assessing the nasal symptoms by PI or delegated personnel or qualified ear, nose, and throat (ENT) specialist Symptoms include color of mucosa, turbinate swelling (middle concha and inferior concha), secretion, infection, post-nasal drip, crusting, sign of bleeding, and polyps.
Time frame: [Day 1 to Day 29]
Viral clearance
Time to clearance of SARS-CoV-2, defined as 2 consecutive negative oropharyngeal swabs by RT-PCR test and report as cycle threshold (CT)
Time frame: [Day 1 to Day 29]
Viral clearance rate by PCR
Changes of CT of RdRp (a.k.a. nsp12) N and E gene assayed by RT-PCR test
Time frame: [Day 1 to Day 29]
PASS evaluation
Proportion of subjects achieving PASS at each visit
Time frame: [Day 1 to Day 29]
Clinical Progression Scale analysis
Proportion of subjects achieving ≧1 decrease on WHO 11-point Clinical Progression Scale at each visit
Time frame: [Day 1 to Day 29]
Days of COVID-19 symptomatic hospitalization
Days participants in hospital due to infection.
Time frame: [Day 1 to Day 29]
Proportion of COVID-19 symptomatic hospitalization
Proportion of participants has been hospitalized due to infection.
Time frame: [Day 1 to Day 29]
Oxygen supplement treatment
Days of participants receive oxygen supplement.
Time frame: [Day 1 to Day 29]
Oxygen supplement treatment rate
Oxygen supplement receiving rates among infected participants
Time frame: [Day 1 to Day 29]
Symptom relieve days
Time to alleviation of each predefined COVID-19-related symptoms
Time frame: [Day 1 to Day 29]
Symptom severity report
Severity of each targeted COVID-19 symptoms An assessment of common COVID-19-related symptoms according to the FDA Guidance for Industry: Assessing COVID-19-Related Symptoms in Outpatient Adult and Adolescent Subjects in Clinical Trials of Drugs and Biological Products for COVID-19 Prevention or Treatment Symptom Score Guide: 0= None; 1= Mild; 2= Moderately; 3= Severe
Time frame: [Day 1 to Day 29]
Mortality rate report
Proportion of participants with death (all cause)
Time frame: [Day 1 to Day 29]
Anti-SARS-CoV-2 specific IgG assessment
The titers of anti-SARS-CoV-2 specific IgG of each participants are measured with ELISA
Time frame: [Day 1 and Day 29]
Ran from Dec 2022 to primary completion in Aug 2024, 20 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Advagene Biopharma Co. Ltd.